Urothelial Cancer
QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
- Details
ClinicalTrials.gov ID:
NCT04197986
Diagnosis Type:
NA
USOR Number:
- Address
3550 N E Loop 286
Paris, TX 75460
P: (903) 785-0031